We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter (BAX) Hits a 52-Week High: What's Driving the Stock?
Read MoreHide Full Article
Share price of Baxter International Inc. (BAX - Free Report) , a global medical technology company, rallied to a new 52-week high of $51.43 on Mar 8, eventually closing a bit lower at $51.36.
This represents an impressive one-year return of approximately 29%, better than the S&P 500’s 16.9% over the same period. A glimpse at the recent price performance of the stock reveals a solid gain of 14.2% over the last three months, compared with the Zacks classified Medical Product sub-industry’s gain of almost 8.2%.
In fact, since the last earnings release of fourth-quarter fiscal 2016 on Feb 1, the company’s share price has gained 6.8% till yesterday’s close. Currently, Baxter carries a Zacks Rank #3 (Hold). Notably, the stock has a market cap of $27.57 billion.
Recently, Baxter formed a strategic partnership with Taiwan-based process research and development and active pharmaceutical ingredient (API) manufacturer, ScinoPharm Taiwan, Ltd. The alliance aims at developing and commercializing five injectable drugs to be used in a range of cancer treatments, including lung cancer, multiple myeloma and breast cancer (read more: Baxter Partners ScinoPharm, Expands in Generic Injectables).
The partnership is expected to strengthen the company’s position in the huge and growing global market of generic injectables. It will also help Baxter increase patient access to difficult-to-manufacture, high-quality oncolytic medicines.
The company is also well poised on solid sales in its Hospital products and Renal products business segments. In this regard, we note that Hospital product sales in the just-reported fourth quarter increased 1% at constant currency (cc) on a year-over-year basis driven by solid demand for IV solutions, nutritional therapies and IV access administration sets. Meanwhile, renal products sales increased 5% to $1 billion. Renal product sales were driven by peritoneal dialysis products as well as increased global demand for continuous renal replacement therapies.
Additionally, a long-term expected earnings growth rate of 12.08% and an earnings yield of 4.26% compared with the industry’s gain of 1.40%, instills confidence among investors.
Estimate Revision Trend
The estimate revision trend for the stock has been encouraging.
The current quarter has seen four estimates move north over the last two months, with no movement in the opposite direction. As a result, the Zacks Consensus Estimate for the current quarter increased 18.6% to 51 cents per share over the same time frame.
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock represents an impressive one-year return of 89.7%.
Avinger projects sales growth of 30.6% for the current year. The company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. The company posted a positive earnings surprise of 1.6% in the last quarter.
8 Stocks with Huge Profit Potential
Just released: Driverless Cars: Your Roadmap to Mega-Profits Today. In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Baxter (BAX) Hits a 52-Week High: What's Driving the Stock?
Share price of Baxter International Inc. (BAX - Free Report) , a global medical technology company, rallied to a new 52-week high of $51.43 on Mar 8, eventually closing a bit lower at $51.36.
This represents an impressive one-year return of approximately 29%, better than the S&P 500’s 16.9% over the same period. A glimpse at the recent price performance of the stock reveals a solid gain of 14.2% over the last three months, compared with the Zacks classified Medical Product sub-industry’s gain of almost 8.2%.
In fact, since the last earnings release of fourth-quarter fiscal 2016 on Feb 1, the company’s share price has gained 6.8% till yesterday’s close. Currently, Baxter carries a Zacks Rank #3 (Hold). Notably, the stock has a market cap of $27.57 billion.
Baxter International Inc. Price and Consensus
Baxter International Inc. Price and Consensus | Baxter International Inc. Quote
Key Catalysts
Recently, Baxter formed a strategic partnership with Taiwan-based process research and development and active pharmaceutical ingredient (API) manufacturer, ScinoPharm Taiwan, Ltd. The alliance aims at developing and commercializing five injectable drugs to be used in a range of cancer treatments, including lung cancer, multiple myeloma and breast cancer (read more: Baxter Partners ScinoPharm, Expands in Generic Injectables).
The partnership is expected to strengthen the company’s position in the huge and growing global market of generic injectables. It will also help Baxter increase patient access to difficult-to-manufacture, high-quality oncolytic medicines.
The company is also well poised on solid sales in its Hospital products and Renal products business segments. In this regard, we note that Hospital product sales in the just-reported fourth quarter increased 1% at constant currency (cc) on a year-over-year basis driven by solid demand for IV solutions, nutritional therapies and IV access administration sets. Meanwhile, renal products sales increased 5% to $1 billion. Renal product sales were driven by peritoneal dialysis products as well as increased global demand for continuous renal replacement therapies.
Additionally, a long-term expected earnings growth rate of 12.08% and an earnings yield of 4.26% compared with the industry’s gain of 1.40%, instills confidence among investors.
Estimate Revision Trend
The estimate revision trend for the stock has been encouraging.
The current quarter has seen four estimates move north over the last two months, with no movement in the opposite direction. As a result, the Zacks Consensus Estimate for the current quarter increased 18.6% to 51 cents per share over the same time frame.
Stocks to Consider
Better-ranked stocks in the broader medical sector include IDEXX Laboratories, Inc. (IDXX - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corp. . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks (Strong Buy) here.
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock represents an impressive one-year return of 89.7%.
Avinger projects sales growth of 30.6% for the current year. The company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. The company posted a positive earnings surprise of 1.6% in the last quarter.
8 Stocks with Huge Profit Potential
Just released: Driverless Cars: Your Roadmap to Mega-Profits Today. In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>